Agilent Technologies: Mikael Dolsten
Agilent Technologies announced that it elected Mikael Dolsten to its board of directors. Dolsten is chief scientific officer and president of worldwide research, development, and medical at Pfizer, and bings 30 years of pharma experience to the Agilent board. Most recently, he co-led Pfizer's collaboration with BioNTech to develop Comirnaty, the COVID-19 vaccine.
Dolsten has held numerous roles at Pfizer since 2009, including CSO, president of R&D, and senior vice president and division president of biotherapeutics research and development. During his career, he held research leadership positions for Wyeth Pharmaceuticals, Boehringer Ingelheim, AstraZeneca, and Pharmacia & Upjohn, and he is a member of the board of directors for Karyopharm Therapeutics and Vimian Group.